Hereditary Predisposition Plays a Larger Role in SCLC Development Than Previously Recognized and May Inform Personalized Treatment
Kara Nyberg, PhDWhole-exome sequencing reveals that almost half of all patients with small cell lung cancer (SCLC) have a deleterious germline mutation which may be associated with the development of their disease […] Read more
Read the full articles for detailed summaries of each presentation. TALENT: This national lung cancer screening study conducted in Taiwan in 12,011 individuals, uncovered the presence of lung cancer in […] Read more
Patient Research Advocate (PRA) and 12-year survivor, Jill Feldman, discusses scientific and humanistic concerns regarding the ADAURA trials current data on disease-free progression in NSCLC. As a patient, osimertinib has […] Read more
Mobocertinib for Exon 20-Related Lung Cancer of Great Interest to Patients My brother Kevin, who founded the Exon 20 Group at ICAN with me in early 2017, started on mobocertinib […] Read more
Improved Screening Uptake Could Help Double Lung Cancer Survival by 2025
Beth Fand IncollingoBetween 60% and 65% of patients with lung cancer receive their diagnoses at stage III or IV, meaning that one-third are unaware of their disease when radical surgery, either alone […] Read more
Promising Results for Lurbinectedin in SCLC When Paired with Irinotecan
Kara Nyberg, PhDCombined treatment with lurbinectedin and irinotecan appears to pack quite a punch in patients with relapsed small cell lung cancer (SCLC) according to the results of a phase Ib/II trial […] Read more
Deeper Understanding of EGFR Mutation Subgroups Will Further Personalize Treatment for NSCLC
New insights into the types of EGFR mutations that can arise in NSCLC may help guide decisions about the most appropriate targeted drugs for individual patients. A study by Jacqulyne […] Read more
The novel antibody drug conjugate trastuzumab deruxtecan (T-DXd) demonstrated clinically meaningful and promising efficacy in patients with HER2-mutated NSCLC, according to interim results of the DESTINY-Lung01 trial, presented as part […] Read more
The IASLC’s proposed new classification of N descriptor is potentially better at differentiating patients with lung cancer into different stages, according to the results of a study presented during the […] Read more
Although RAS mutations constitute some of the most common genetic alterations in patients with adenocarcinomas, efforts to target the RAS oncoprotein have not proven fruitful, not only in NSCLC but […] Read more